WARNINGREDOSING CAN TRIGGER PSYCHOSIS

PCP-like dissociatives can cause mania, paranoia, or psychosis that outlasts the high. High doses, redosing, and sleep loss raise the risk.

4-MeO-PCP

4-Methoxyphencyclidine

Methoxydine, 4-Methoxy-PCP

Psychoactive Class

Dissociative Hallucinogen

Chemical Class

Arylcyclohexylamine

4-MeO-PCP is an arylcyclohexylamine synthetic dissociative that can produce hallucinogenic and anesthetic effects. First synthesized in 1965 by Parke-Davis chemist Victor Maddox, it became the first arylcyclohexylamine research chemical sold online when it appeared in late 2008. It is reported to have reduced potency relative to PCP. Dosage information remains tentative, potentially due to variations in the potency of available supplies.

Dosage & Duration

Dosage

Doses are population estimates that vary widely between individuals.

Threshold~25 mg

Light25-75 mg

Moderate75-150 mg

Strong150-250 mg

Heavy250+ mg

Dosage information for 4-MeO-PCP remains poorly characterized, and some user reports may involve misidentified substances. Sensitivity varies considerably between individuals, and dose-response relationships appear inconsistent.

Duration

Onset45-120 minutes

Come Up1-2 hours

Peak3-7 hours

Offset6-10 hours

After Effects6-12 hours

Total12-20 hours

Subjective Effects

Effects vary widely by individual, dose, and context.

Forked from Subjective Effect Documentation work

by Josie KinsAugust 2016.

Reagent Testing

Expected colorimetric results for common reagent tests. Colors show reaction change over 1–2 minutes.

Mecke(ME)

Mandelin(MD)

Liebermann(LB)

Froe(FR)

PROtestkit.eu

Pharmacology

Pharmacodynamics

4-MeO-PCP acts primarily as an NMDA receptor antagonist.¹ Its NMDA affinity is lower than that of PCP but higher than that of ketamine. The compound also binds with notable affinity to σ1 and σ2 receptors, and shows moderate affinity for the norepinephrine and serotonin transporters.¹ It is considered a relatively selective NMDA receptor ligand, lacking appreciable affinity for the dopamine transporter.¹

Pharmacokinetics

4-MeO-PCP is orally active, indicating sufficient oral bioavailability for pharmacological effects. There have been no studies on the pharmacokinetic profile of 4-MeO-PCP and the metabolism of 4-MeO-PCP is unknown.

Metabolitesnone documented yet

Interactions

Dangerous

Highest risk

These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.

DepressantsStimulants

TripSit

Tolerance

Tolerance timelines are rules of thumb, not exact schedules, and vary widely between individuals and use patterns.

Full Tolerance

With sustained repeated use, many effects may weaken, requiring higher doses for comparable results.

Baseline Reset

1-2 weeks

Half Tolerance

3-7 days

Cross Tolerance

Dissociatives

Harm Potential

Addiction & Dependence

Psychological

Moderate

Chronic use can be moderately addictive with high potential for abuse and is capable of causing psychological dependence among certain users. Cravings may occur if usage is suddenly stopped.

Physical

Low

Withdrawal effects have been reported upon cessation of chronic use, though specific physical withdrawal symptoms are not well characterized due to limited research history.

Toxicity

Urinary System

Repeated excessive use over extended periods may cause bladder and urinary tract problems similar to those seen with ketamine, including urinary frequency and urgency, pelvic and bladder pain, hematuria, and incontinence; these effects can be avoided by limiting use to less than weekly.

Psychosis Risk

Psychotic episodes, disturbing hallucinations, delusions, anxiety, and paranoia are reported as potential negative effects. Risk of adverse psychological reactions increases with higher doses and redosing.

History & Culture

4-MeO-PCP was originally synthesized in 1965 by Victor Maddox, a medicinal chemist working at the pharmaceutical company Parke-Davis. The compound remained largely obscure for decades following its initial creation.…

Legality

By Country

United StatesRestricted

United States Controlled Substances Act analogue provision, 21 USC §§802(32), 813¹⁹²⁰

The federal analogue statute is fact- and intent-dependent; this result does not assert that every possession or non-human-consumption use of 4-MeO-PCP is federally prosecutable. State law was not substituted for the federal conclusion.

GermanyIllegal (analog/blanket ban)

Neue-psychoaktive-Stoffe-Gesetz (NpSG), consolidated official text⁴

The law's generic structural definition is the legal basis rather than a named 4-MeO-PCP entry; §3's listed conduct prohibition has statutory exceptions for recognized commercial, industrial or scientific uses.

SwitzerlandRestrictedBetäubungsmittelverzeichnisverordnung…

Betäubungsmittelverzeichnisverordnung (BetmVV-EDI; SR 812.121.11), Articles 1–2 and Annex 6 Verzeichnis e item 103, consolidated text standing 13 March 2026^67891011

Repaired from the refuted overbroad characterization. The exact substance is expressly named as item 103 in the binding BetmVV-EDI Annex 6 Verzeichnis e. Verzeichnis e is a distinct Article 7 BetmG category whose materials/products are subject to the control measures applicable to Verzeichnis-a narcotics and require the applicable EDI authorization framework. The cited item 103 line does not state a general industrial-use exception, so no such exception is asserted. This is not an unqualified claim that every act involving 4-MeO-PCP is categorically prohibited, and Verzeichnis e must not be equated with Verzeichnis d.

United KingdomClass B

Controlled under the Misuse of Drugs Act 1971. Covered by the arylcyclohexylamine generic clause added by S.I. 2013/239, which came into effect on February 26, 2013.¹⁸ This clause encompasses derivatives of 1-phenylcyclohexylamine where the amine has been replaced with a piperidyl group and further substituted in the phenyl ring with an alkoxy substituent.¹⁸ Possession, production, supply, and importation are prohibited.

ChileIllegal

Prohibited under Ley 20000 (the Chilean drug control law), which explicitly covers all esters and ethers of phencyclidine.³ As 4-MeO-PCP is an ether of PCP, it falls under this provision.

SwedenIllegalNarcotic

Förordning (1992:1554) om kontroll av narkotika, 2 § and Bilaga 1⁵

Sweden's public health agency recommended classifying 4-MeO-PCP as a hazardous substance on November 10, 2014.

TurkeyIllegal4-MeO-PCP is the named compound 1-[1-(4-methoxyphenyl)cyclohexyl]piperidine in Annex 2 to Council of Ministers Decision No. 2013/5742 (the official EGM/TUBIM report's item 111, printed as 'MeO-PCP'). NIH PubChem CID 15100753 independently identifies 4-MeO-PCP (also methoxydine/4-methoxyphencyclidine) with that same IUPAC name. The Turkish entry is an individually named new-psychoactive-substance control under Law No. 2313; the inspected Turkish materials do not assign it a separate numbered schedule or separate analogue designation.

Law No. 2313 on the Control of Narcotic Drugs (Uyuşturucu Maddelerin Murakabesi Hakkında Kanun), as amended by Council of Ministers Decision No. 2013/5742 dated 16 December 2013 and published in Official Gazette No. 28893 on 25 January 2014; Turkish Penal Code No. 5237 (TCK) Articles 188 and 191 for unauthorized manufacture, import/export, supply/trade, possession and use.^121314151617

The packet's Illegal statement is supported, but the legal basis is more precise than a generic claim that all possession is prohibited: 4-MeO-PCP is individually named in Annex 2 item 111 to Decision 2013/5742 and thereby brought under Law No. 2313. Turkey's NPS framework also uses generic classification (in operation since 2015), but no separate generic or analogue designation for this named entry was identified. The latest official EGM report inspected records continuing EWS and Law No. 2313 inclusion through 31 July 2025; no repeal or exclusion of the specifically named entry was identified in the official materials inspected. TCK Article 188 penalties are conduct-specific and include daily fines; Article 191 personal-use possession/use is 2-5 years subject to the statutory five-year deferred-prosecution, supervised-release and treatment mechanisms. The 188/4(a) half-increase for listed substance classes should not be assumed for 4-MeO-PCP merely from its NPS status. This is a legal-status summary, not advice on a particular case.

References

Source Pages

Citations

Suggest an edit

Spotted a mistake, an outdated claim, or something missing from the 4-MeO-PCP article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.

Wish to give generalised feedback? You can do so here.